Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation

Yonson Ku, Nobuya Kusunoki, Tetsushi Kitagawa, Ichiro Maeda, Takumi Fukumoto, Takeshi Iwasaki, Masahiro Tominaga, Yasuyuki Suzuki, Yoshikazu Kuroda, Yusuke Tanigawara, Yoichi Saitoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We investigated the pharmacokinetics of cytotoxic anticancer agents administered under anhepatic conditions. Beagle dogs underwent either a sham operation consisting of laparotomy only (control group, n = 11) or a laparotomy and total hepatectomy under venovenous bypass (anhepatic group, n 12). Each dog received a bolus intravenous injection of either Adriamycin (1 mg/kg) or cisplatin (1 mg/kg). The plasma and urine concentrations of each drug were measured at intervals for up to 2 h after drug injection. The dogs given Adriamycin were then sacrificed to determine tissue drug concentrations in the liver (controls only), spleen, kidney, heart, lung, skeletal muscle and small intestine. The control and anhepatic groups showed similar Adriamycin profiles during the initial 5 min after drug injection. However, subsequently, the plasma Adriamycin concentrations remained persistently higher in the anhepatic dogs than in the controls, yielding a two-fold elevation of the mean area under the concentration-time curve in the anhepatic group (P<0.01 vs controls). The renal clearance values did not significantly differ between the two groups. The tissue Adriamycin concentrations in all measured organs, excluding the liver, were higher in the anhepatic group than in the controls. In a second set of experiments with cisplatin, the plasma platinum concentrations did not significantly differ between the two groups throughout the time course. However, the renal clearance of platinum in the anhepatic dogs showed a fourfold increase compared with that in the controls (P<0.01). These pharmacokinetics data suggest that Adriamycin carries the risk of increased systemic toxicities, while cisplatin may be associated with increased renal toxicity when administered during the anhepatic period of liver transplantation.

Original languageEnglish
Pages (from-to)457-462
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume40
Issue number6
DOIs
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Pharmacokinetics
Chemotherapy
Liver
Liver Transplantation
Doxorubicin
Cisplatin
Drug Therapy
Dogs
Kidney
Platinum
Pharmaceutical Preparations
Laparotomy
Control Groups
Plasmas
Toxicity
Injections
Tissue
Cytotoxins
Hepatectomy
Intravenous Injections

Keywords

  • Adriamycin
  • Anhepatic chemotherapy
  • Cisplatin
  • Hepatocellular carcinoma
  • Liver transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Ku, Y., Kusunoki, N., Kitagawa, T., Maeda, I., Fukumoto, T., Iwasaki, T., ... Saitoh, Y. (1997). Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation. Cancer Chemotherapy and Pharmacology, 40(6), 457-462. https://doi.org/10.1007/s002800050687

Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation. / Ku, Yonson; Kusunoki, Nobuya; Kitagawa, Tetsushi; Maeda, Ichiro; Fukumoto, Takumi; Iwasaki, Takeshi; Tominaga, Masahiro; Suzuki, Yasuyuki; Kuroda, Yoshikazu; Tanigawara, Yusuke; Saitoh, Yoichi.

In: Cancer Chemotherapy and Pharmacology, Vol. 40, No. 6, 1997, p. 457-462.

Research output: Contribution to journalArticle

Ku, Y, Kusunoki, N, Kitagawa, T, Maeda, I, Fukumoto, T, Iwasaki, T, Tominaga, M, Suzuki, Y, Kuroda, Y, Tanigawara, Y & Saitoh, Y 1997, 'Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation', Cancer Chemotherapy and Pharmacology, vol. 40, no. 6, pp. 457-462. https://doi.org/10.1007/s002800050687
Ku, Yonson ; Kusunoki, Nobuya ; Kitagawa, Tetsushi ; Maeda, Ichiro ; Fukumoto, Takumi ; Iwasaki, Takeshi ; Tominaga, Masahiro ; Suzuki, Yasuyuki ; Kuroda, Yoshikazu ; Tanigawara, Yusuke ; Saitoh, Yoichi. / Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation. In: Cancer Chemotherapy and Pharmacology. 1997 ; Vol. 40, No. 6. pp. 457-462.
@article{aa7086d12aeb4e4082873340e6258135,
title = "Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation",
abstract = "We investigated the pharmacokinetics of cytotoxic anticancer agents administered under anhepatic conditions. Beagle dogs underwent either a sham operation consisting of laparotomy only (control group, n = 11) or a laparotomy and total hepatectomy under venovenous bypass (anhepatic group, n 12). Each dog received a bolus intravenous injection of either Adriamycin (1 mg/kg) or cisplatin (1 mg/kg). The plasma and urine concentrations of each drug were measured at intervals for up to 2 h after drug injection. The dogs given Adriamycin were then sacrificed to determine tissue drug concentrations in the liver (controls only), spleen, kidney, heart, lung, skeletal muscle and small intestine. The control and anhepatic groups showed similar Adriamycin profiles during the initial 5 min after drug injection. However, subsequently, the plasma Adriamycin concentrations remained persistently higher in the anhepatic dogs than in the controls, yielding a two-fold elevation of the mean area under the concentration-time curve in the anhepatic group (P<0.01 vs controls). The renal clearance values did not significantly differ between the two groups. The tissue Adriamycin concentrations in all measured organs, excluding the liver, were higher in the anhepatic group than in the controls. In a second set of experiments with cisplatin, the plasma platinum concentrations did not significantly differ between the two groups throughout the time course. However, the renal clearance of platinum in the anhepatic dogs showed a fourfold increase compared with that in the controls (P<0.01). These pharmacokinetics data suggest that Adriamycin carries the risk of increased systemic toxicities, while cisplatin may be associated with increased renal toxicity when administered during the anhepatic period of liver transplantation.",
keywords = "Adriamycin, Anhepatic chemotherapy, Cisplatin, Hepatocellular carcinoma, Liver transplantation",
author = "Yonson Ku and Nobuya Kusunoki and Tetsushi Kitagawa and Ichiro Maeda and Takumi Fukumoto and Takeshi Iwasaki and Masahiro Tominaga and Yasuyuki Suzuki and Yoshikazu Kuroda and Yusuke Tanigawara and Yoichi Saitoh",
year = "1997",
doi = "10.1007/s002800050687",
language = "English",
volume = "40",
pages = "457--462",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of Adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation

AU - Ku, Yonson

AU - Kusunoki, Nobuya

AU - Kitagawa, Tetsushi

AU - Maeda, Ichiro

AU - Fukumoto, Takumi

AU - Iwasaki, Takeshi

AU - Tominaga, Masahiro

AU - Suzuki, Yasuyuki

AU - Kuroda, Yoshikazu

AU - Tanigawara, Yusuke

AU - Saitoh, Yoichi

PY - 1997

Y1 - 1997

N2 - We investigated the pharmacokinetics of cytotoxic anticancer agents administered under anhepatic conditions. Beagle dogs underwent either a sham operation consisting of laparotomy only (control group, n = 11) or a laparotomy and total hepatectomy under venovenous bypass (anhepatic group, n 12). Each dog received a bolus intravenous injection of either Adriamycin (1 mg/kg) or cisplatin (1 mg/kg). The plasma and urine concentrations of each drug were measured at intervals for up to 2 h after drug injection. The dogs given Adriamycin were then sacrificed to determine tissue drug concentrations in the liver (controls only), spleen, kidney, heart, lung, skeletal muscle and small intestine. The control and anhepatic groups showed similar Adriamycin profiles during the initial 5 min after drug injection. However, subsequently, the plasma Adriamycin concentrations remained persistently higher in the anhepatic dogs than in the controls, yielding a two-fold elevation of the mean area under the concentration-time curve in the anhepatic group (P<0.01 vs controls). The renal clearance values did not significantly differ between the two groups. The tissue Adriamycin concentrations in all measured organs, excluding the liver, were higher in the anhepatic group than in the controls. In a second set of experiments with cisplatin, the plasma platinum concentrations did not significantly differ between the two groups throughout the time course. However, the renal clearance of platinum in the anhepatic dogs showed a fourfold increase compared with that in the controls (P<0.01). These pharmacokinetics data suggest that Adriamycin carries the risk of increased systemic toxicities, while cisplatin may be associated with increased renal toxicity when administered during the anhepatic period of liver transplantation.

AB - We investigated the pharmacokinetics of cytotoxic anticancer agents administered under anhepatic conditions. Beagle dogs underwent either a sham operation consisting of laparotomy only (control group, n = 11) or a laparotomy and total hepatectomy under venovenous bypass (anhepatic group, n 12). Each dog received a bolus intravenous injection of either Adriamycin (1 mg/kg) or cisplatin (1 mg/kg). The plasma and urine concentrations of each drug were measured at intervals for up to 2 h after drug injection. The dogs given Adriamycin were then sacrificed to determine tissue drug concentrations in the liver (controls only), spleen, kidney, heart, lung, skeletal muscle and small intestine. The control and anhepatic groups showed similar Adriamycin profiles during the initial 5 min after drug injection. However, subsequently, the plasma Adriamycin concentrations remained persistently higher in the anhepatic dogs than in the controls, yielding a two-fold elevation of the mean area under the concentration-time curve in the anhepatic group (P<0.01 vs controls). The renal clearance values did not significantly differ between the two groups. The tissue Adriamycin concentrations in all measured organs, excluding the liver, were higher in the anhepatic group than in the controls. In a second set of experiments with cisplatin, the plasma platinum concentrations did not significantly differ between the two groups throughout the time course. However, the renal clearance of platinum in the anhepatic dogs showed a fourfold increase compared with that in the controls (P<0.01). These pharmacokinetics data suggest that Adriamycin carries the risk of increased systemic toxicities, while cisplatin may be associated with increased renal toxicity when administered during the anhepatic period of liver transplantation.

KW - Adriamycin

KW - Anhepatic chemotherapy

KW - Cisplatin

KW - Hepatocellular carcinoma

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=9844256096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844256096&partnerID=8YFLogxK

U2 - 10.1007/s002800050687

DO - 10.1007/s002800050687

M3 - Article

C2 - 9332458

AN - SCOPUS:9844256096

VL - 40

SP - 457

EP - 462

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -